Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Pliant Therapeutics (PLRX – Research Report) received a Hold rating and price target from Needham analyst Joseph Stringer today. The ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report) and Capricor ...

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Kansas City Life Insurance Company recorded a net loss of $12.6 million or $1.30 per share in the fourth quarter of 2024, down from net income of $49.1 million or $5.07 per share in the fourth quarter ...

Albertsons Companies Inc. will replace Aspen Technology Inc. (NASD: AZPN) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, March 11. S&P 500 constituent Emerson Electric Co.

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra ...